Anheuser-Busch InBev SA/NV (BUD) Stock Analysis
Is BUD a good investment?
Anheuser-Busch InBev SA/NV (BUD) has a Plutrex AI rating of 79.0/100 as of October 02, 2026, indicating a Buy consensus. The stock is not classified as halal-compliant. Key strength: PEG of 1.17 is 42.8% below the sector average of 2.05 — BUD is the most attractively growth-adjusted valued stock in the alcoholic beverages peer group, growing 5-year EPS at 13.44% vs. peer avg 11.81% while paying a lower PE (15.73x vs. 16.87x peer avg); analyst consensus target upgrade from $90.75 to $97.00 (+6.9%) combined with a 5.7% stock price decline since prior report has widened implied upside to 32.8%. Main concern: Legacy debt structural drag: the 12.4pp gap between operating margin (27.34%) and net margin (14.9%) reflects persistent below-the-line interest costs from the 2008 AB InBev merger; ROE of 10.71% remains at parity with peers despite massively superior margins, confirming goodwill/intangible asset burden suppresses equity returns; D/E of 0.74 is manageable but rate environment sensitivity remains — any macro deterioration amplifies this structural cost headwind that has been UNCHANGED across three consecutive reports.
Investment Summary
AB InBev (BUD) at $73.02 presents a compelling buy case anchored in three converging signals: (1) Deep valuation discount — P/E of 15.73x is 6.7% below the industry average of 16.87x while simultaneously growing EPS 50.4% faster than peers; PEG of 1.17 is 42.8% below the sector average of 2.05, a rare quality-at-discount configuration. (2) Margin supremacy — gross margin 56.5% (+16.9% vs. peers), operating margin 27.34% (+44.1% vs. peers), net margin 14.9% (+76.2% vs. peers) confirm structural competitive moat. (3) Analyst target upgrade to $97.00 from $90.75 (+6.9%) implies 32.8% upside, materially above the 17.2% implied in the prior report. The stock declined 5.7% ($77.42→$73.02) while the analyst consensus target rose 6.9% — this divergence widens the risk-reward materially. FCF of $13.726B at the current price implies approximately an 18.8% FCF yield on market cap, which is exceptional for a mega-cap consumer staples franchise. The 'Reignite Phase' Capital Markets Day strategy, Stella Artois Netflix collaboration, and non-alcoholic expansion all reinforce the multi-year growth thesis without new risks.
Key Strengths
- PEG of 1.17 is 42.8% below the sector average of 2.05 — BUD is the most attractively growth-adjusted valued stock in the alcoholic beverages peer group, growing 5-year EPS at 13.44% vs. peer avg 11.81% while paying a lower PE (15.73x vs. 16.87x peer avg); analyst consensus target upgrade from $90.75 to $97.00 (+6.9%) combined with a 5.7% stock price decline since prior report has widened implied upside to 32.8%
- Three-dimensional profitability leadership: gross margin 56.5% (+16.9% vs. peers at 48.35%), operating margin 27.34% (+44.1% vs. peers at 18.97%), net margin 14.9% (+76.2% vs. peers at 8.46%) — simultaneously best-in-class on all three profitability layers at global scale, confirmed by $13.726B FCF (18.8% FCF yield at $73.02)
- News sentiment 100/100 with zero negative articles and substantive positive catalysts: 'Reignite Phase' Capital Markets Day provides 5%-9% EBIT growth target anchoring the 13.44% 5-year EPS CAGR; Stella Artois/Netflix collaboration ('AB InBev's Stella Artois enters first multi-market brand collaboration with Netflix, partnering on The Gentlemen Season 2') expands brand reach; non-alcoholic expansion ('Can AB InBev's Zero-Alcohol Push Win Health-Conscious Consumers?') directly addresses secular demand headwind and targets incremental revenue from a structurally growing consumer segment
Key Concerns
- Legacy debt structural drag: the 12.4pp gap between operating margin (27.34%) and net margin (14.9%) reflects persistent below-the-line interest costs from the 2008 AB InBev merger; ROE of 10.71% remains at parity with peers despite massively superior margins, confirming goodwill/intangible asset burden suppresses equity returns; D/E of 0.74 is manageable but rate environment sensitivity remains — any macro deterioration amplifies this structural cost headwind that has been UNCHANGED across three consecutive reports
- Technical momentum deterioration: stock has declined 5.7% over 7 days ($77.42→$73.02) with no fundamental catalyst justifying the selloff — this creates near-term uncertainty about the floor; near-term EPS growth of 11.21% represents deceleration from historical 22.8% YoY, and the 5-year 13.44% CAGR requires reacceleration beyond the near-term year, creating execution risk on the back-loaded growth thesis
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
Profitability: ROE of 10.71% is at industry parity (peer avg 10.70%) — the one metric where BUD does not distinguish itself, reflecting ~$50B+ in goodwill/intangibles from the 2008 merger diluting equity returns. However, this is offset by gross margin of 56.5% (vs. industry 48.35%), operating margin of 27.34% (vs. industry 18.97%), and net margin of 14.9% (vs. industry 8.46%) — three-dimensional profitability leadership unique in the sector. Health: D/E of 0.74 is marginally below peer average of 0.77; cash position of $8.011B provides liquidity; FCF of $13.726B (~18.8% FCF yield at $73) is exceptional but legacy acquisition debt creates a structural 12.4pp drag between operating margin (27.3%) and net margin (14.9%). Valuation: P/E of 15.73x at 5-year EPS CAGR of 13.44% yields PEG of 1.17 — approaching but not quite at deep-value threshold of 1.0x, but contextualized against peers at 2.05 PEG, BUD is dramatically cheaper on a growth-adjusted basis. P/B of 1.54 provides book-value downside protection. Growth: Next-year EPS growth 11.21% (vs. peer avg 7.45%); 5-year EPS CAGR 13.44% (vs. peer avg 11.81%); revenue growth 11.0% (vs. peer avg 5.95%) — BUD grows faster than peers on every forward metric while trading at a PEG discount. Analyst consensus target $97.00 vs. current $73.02 = 32.8% implied upside.
News Sentiment
AB InBev is firing on all cylinders strategically, even as its stock has taken an unexpected tumble. The world's largest brewer just unveiled its ambitious 'Reignite Phase' at a Capital Markets Day event, laying out a blueprint for 5% to 9% annual profit growth that has impressed analysts enough to raise their price target from $90.75 to $97 — a nearly 7% upgrade. Yet somehow, the stock is trading 33% below that target at just $73. The company is making bold moves to stay relevant in a changing world. Stella Artois just landed a splashy marketing deal with Netflix, partnering on 'The Gentlemen Season 2' — the kind of pop culture moment that money can't easily buy and that builds brand equity with younger audiences. Meanwhile, AB InBev is diving headfirst into the booming non-alcoholic space, asking 'Can AB InBev's Zero-Alcohol Push Win Health-Conscious Consumers?' — a question the company is answering with real product investment and distribution muscle. From a financial standpoint, the story is compelling. The company generates nearly $14 billion in free cash flow annually, its profit margins dwarf competitors by a wide margin, and it's growing revenue twice as fast as the average rival. The 'Reignite' strategy, combined with a $600 million U.S. market commitment and a Michelob Ultra production expansion, signals management is thinking long-term. For patient investors, the gap between reality and analyst expectations looks like an opportunity.
Risk Assessment
PRIMARY RISK: Legacy debt structural drag — the 12.4pp operating-to-net margin gap ($13.7B FCF notwithstanding) means any sustained rise in interest rates or credit market stress would compress net margins further and suppress the ROE recovery thesis. SECONDARY RISK: Secular alcohol consumption decline — 'Smaller packs, more protein: AB InBev to adapt drinks to shifting tastes' reflects real demand-side headwinds that non-alcoholic expansion is addressing but has not yet fully offset; execution on the Reignite Phase diversification strategy is not guaranteed. TERTIARY RISK: Technical momentum negative — 5.7% decline in 7 days with no fundamental catalyst could indicate institutional selling or broader consumer staples rotation; a breach below $70 would challenge the bull thesis and warrant stop review. MITIGATION: $8.011B cash + $13.726B FCF provides enormous financial flexibility to deleverage, defend dividends, and fund strategic pivots; the 32.8% gap between current price ($73.02) and analyst consensus ($97.00) provides substantial margin of safety. Position size held at 3.0% of portfolio reflects medium conviction — appropriate given structural debt concern and near-term price weakness.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is BUD a halal stock?
No, Anheuser-Busch InBev SA/NV (BUD) is currently not classified as halal by AAOIFI criteria.
What is Plutrex's AI rating for BUD?
Anheuser-Busch InBev SA/NV (BUD) has a Plutrex AI rating of 79.0/100 with a Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is BUD a good investment?
According to Plutrex AI, BUD has a Buy rating (79.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in BUD?
US stocks like BUD can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in BUD?
Plutrex AI identifies the main risks for BUD by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.